It is small cap company listed on BSE and NSE engaged in research, production and marketing pharmaceutical products and formulations. The company has entered into an agreement with eight international pharma companies to source their requirements of clarithomycin, fexofinadine, roxithromycin and candesartan. The chandigarh based company has manufacturing facilities in Punjab and Jammu. The company has entered into marketing agreement with some major international pharma companies to market their products across the globe.
The market capitalisation of the company is Rs.342.4 having PE ratio of 3.91 against industry PE of 11.42. The current market price of the scrip is Rs. 100.65 as on 20.07.2011 on NSE. The financials of the company is strong and can be seen as the revenue from the operations of the company increased from Rs.462.97 crores in FY 2008 to Rs.1031.21 crores in FY2011. Accordingly the net profit of the company also grown from Rs. 31.02 crores to Rs.87.62 crores during the same period.
EPS of the company has increased from Rs. 12.91 in FY 2008 to Rs. 25.60 in FY 2011.The financial ratios like current ratio of the company is 2.19 showing good liquidity and return on long term funds utilised by the company comes to 13.09% as on balance sheet drawn on 31.03.2010.
In June 2010, SBI Magnum fund has acquired 137.145 shares of the company showing confidence in the future potential of the company.
fraud promoters -if you inquire from anyone in business circles in chendigarh they will tell you why you want to recommend such stocks?
ReplyDelete